このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Merus 過去の業績
過去 基準チェック /06
Merusの収益は年間平均-28.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 7.8%割合で 増加しています。
主要情報
-28.6%
収益成長率
-11.3%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 7.8% |
| 株主資本利益率 | -42.8% |
| ネット・マージン | -390.4% |
| 前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04収支内訳
収支内訳
Merus の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 24 | 38 | -150 | 61 | 0 |
| 31 Dec 23 | 44 | -155 | 60 | 0 |
| 30 Sep 23 | 46 | -177 | 59 | 0 |
| 30 Jun 23 | 41 | -178 | 59 | 0 |
| 31 Mar 23 | 43 | -152 | 56 | 0 |
| 31 Dec 22 | 42 | -131 | 52 | 0 |
| 30 Sep 22 | 46 | -64 | 48 | 0 |
| 30 Jun 22 | 53 | -54 | 45 | 0 |
| 31 Mar 22 | 52 | -76 | 43 | 0 |
| 31 Dec 21 | 49 | -67 | 41 | 0 |
| 30 Sep 21 | 43 | -80 | 40 | 0 |
| 30 Jun 21 | 38 | -89 | 39 | 0 |
| 31 Mar 21 | 32 | -79 | 36 | 0 |
| 31 Dec 20 | 30 | -86 | 36 | 0 |
| 30 Sep 20 | 29 | -83 | 35 | 0 |
| 30 Jun 20 | 28 | -69 | 34 | 0 |
| 31 Mar 20 | 29 | -65 | 34 | 0 |
| 31 Dec 19 | 31 | -55 | 32 | 0 |
| 30 Sep 19 | 37 | -32 | 43 | 0 |
| 30 Jun 19 | 35 | -34 | 38 | 0 |
| 31 Mar 19 | 36 | -26 | 33 | 0 |
| 31 Dec 18 | 38 | -28 | 29 | 0 |
| 30 Sep 18 | 34 | -41 | 13 | 0 |
| 30 Jun 18 | 33 | -45 | 14 | 0 |
| 31 Mar 18 | 34 | -66 | 16 | 0 |
| 31 Dec 17 | 26 | -78 | 17 | 0 |
| 30 Sep 17 | 18 | -100 | 18 | 0 |
| 30 Jun 17 | 12 | -87 | 13 | 0 |
| 31 Mar 17 | 6 | -66 | 9 | 0 |
| 31 Dec 16 | 3 | -50 | 5 | 0 |
| 30 Sep 16 | 4 | -25 | 2 | 0 |
| 30 Jun 16 | 3 | -26 | 2 | 0 |
| 31 Mar 16 | 3 | -27 | 1 | 0 |
| 31 Dec 15 | 2 | -25 | 1 | 0 |
| 30 Sep 15 | 2 | -25 | 1 | 0 |
| 30 Jun 15 | 2 | -23 | -1 | 0 |
| 31 Mar 15 | 1 | -20 | 0 | 0 |
| 31 Dec 14 | 2 | -21 | 1 | 0 |
| 31 Dec 13 | 1 | -14 | 4 | 0 |
質の高い収益: MRUSは現在利益が出ていません。
利益率の向上: MRUSは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: MRUSは利益が出ておらず、過去 5 年間で損失は年間28.6%の割合で増加しています。
成長の加速: MRUSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: MRUSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: MRUSは現在利益が出ていないため、自己資本利益率 ( -42.83% ) はマイナスです。